Framing Benefits in Decision Aids: Effects of Varying Contextualizing Statements on Decisions About Sacubitril-Valsartan for Heart Failure

Author:

Thomson Mary C.1,Allen Larry A.2,Halpern Scott D.3,Ko Yi-An4,Matlock Daniel D.25ORCID,Mitchell Andrea R.6,Moore Miranda A.7ORCID,Morris Alanna A.6,Rao Birju R.6,Scherer Laura D.2ORCID,Speight Candace D.6,Ubel Peter A.8,Dickert Neal W.69ORCID

Affiliation:

1. Medical College of Georgia, Augusta, Georgia

2. Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado

3. Palliative and Advanced Illness Research (PAIR) Center and Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania

4. Rollins School of Public Health, Emory University, Atlanta, Georgia

5. VA Eastern Colorado Geriatric Research Education and Clinical Center, Denver, Colorado

6. Department of Medicine, Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia

7. Department of Family and Preventive Medicine, Emory University School of Medicine, Atlanta, Georgia

8. Duke University Fuqua School of Business, Sanford School of Public Policy, Durham, North Carolina

9. Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, Georgia

Abstract

Background. Presenting numeric data alone may result in patients underappreciating clinically significant benefits. Contextualizing statements to counter this may raise concern about absence of neutrality. These issues arose during construction of a decision aid for sacubitril-valsartan, a heart failure medication associated with a ∼3% absolute reduction in 2-year mortality that carries high out-of-pocket cost. A contextualizing statement framing this as a “pretty big benefit” was incorporated. The impact of statements like this within decision aids is unknown. Objective. This online Qualtrics survey sought to deepen understanding of benefit framing by testing the impact of varying contextualizing statements within a decision aid for sacubitril-valsartan. Design. Participants were randomly assigned to receive one of six abbreviated versions of a decision aid for sacubitril-valsartan that varied only by contextualizing statement (ranging from strongly neutral to strongly positive and using relative and absolute risk reductions). Participants were asked to answer questions regarding the likelihood of taking the medication at a cost of $50/month and their perception of the drug’s benefits. Results. A total of 1873 participants who were demographically similar to the heart failure population completed the survey. Fifty-four percent were willing to take sacubitril-valsartan at $50/month. Each of the five experimental contextualizing statements was compared with the baseline version; no significant differences were observed in reported likelihood of taking sacubitril-valsartan. After controlling for demographics and covariates, group assignment did not predict likelihood of taking the medication. Higher income, better self-reported health status, and younger age were associated with increased likelihood of taking sacubitril-valsartan. Limitations. This study used a hypothetical scenario and evaluated one method of delivering contextualizing statements. Conclusions. Contextualizing statements as tested within this decision aid did not affect decision making.

Publisher

SAGE Publications

Subject

Public Health, Environmental and Occupational Health,Health Policy

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3